Document Detail

Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients.
MedLine Citation:
PMID:  23150178     Owner:  NLM     Status:  Publisher    
Recently, it was reported that soluble MICB (sMICB) may impair tumor immunogenicity by reducing natural killer group 2D ligand densities on malignant cells. The aim of this study was to elucidate the role of sMICB in melanoma patients. In the present study, we determined sMICB serum concentration in 125 melanoma patients of different clinical stages of disease compared with 30 healthy controls using an ELISA. The correlations between sMICB serum concentration and clinicopathologic variables were analyzed. sMICB serum level was significantly elevated (P < 0.0005) in melanoma patients (mean ± SE = 8.60 ± 0.26 ng/ml) compared with healthy controls (mean ± SE = 6.27 ± 0.25 ng/ml). Univariate analysis revealed a correlation of sMICB serum concentration with advanced stages of disease (P = 0.009). Only a slight increase in sMICB serum level (P = 0.057) could be observed in regard to the tumor burden. Patients undergoing current treatment with cytostatics (n = 18) revealed a strong increase in sMICB serum level (P < 0.0005), whereas treatment with IFN-α alone or combined with cytostatics (n = 19) showed no change in serum sMICB concentration. According to Kaplan-Meier analysis, elevated sMICB serum levels were associated with a poor overall and a progression-free survival. Multivariate analysis revealed sMICB serum concentration as an independent predictive factor for progression-free and overall survival. Our results show a prognostic relevance of serum sMICB in melanoma patients, indicating that the evaluation of sMICB serum level may be important for the selection of therapeutic strategies.
Bao-Jin Wu; Wen-Peng Li; Cheng Qian; Wei Ding; Zhong-Wen Zhou; Hua Jiang
Related Documents :
581118 - The determination of 5alpha-androstane-3alpha, 17beta-diol in human plasma by radioimmu...
23944768 - Evaluation of a dried blood and plasma collection device, sampletanker(®), for hiv typ...
23803798 - Chronotype as modulator of morning serum melatonin levels.
24531408 - Dioxin, furan and pcb serum levels in a south african tswana population: comparing the ...
393048 - Pituitary responsiveness to luteinizing hormone-releasing hormone during treatment with...
7154618 - Serum lipoproteins in patients with mild renal disease treated with the diuretic muzoli...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-14
Journal Detail:
Title:  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine     Volume:  -     ISSN:  1423-0380     ISO Abbreviation:  Tumour Biol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8409922     Medline TA:  Tumour Biol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Plastic Surgery, Huashan Hospital, Fudan University, No. 12, Wulumuqi Zhong Rd., Shanghai, 200040, China,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lack of mutational events of RAS genes in sporadic thyroid cancer but high risk associated with HRAS...
Next Document:  cAMP response element binding protein H mediates fenofibrate-induced suppression of hepatic lipogene...